In short
Alrefimotide is an investigational drug being studied in clinical trials for various types of cancer, including non-small cell lung cancer, malignant pleural mesothelioma, and ovarian cancer. This article will provide an overview of the ongoing research into alrefimotide's potential as a cancer treatment, focusing on its use in combination with other therapies and its safety profile.
At a glance
- Drug Name
- Alrefimotide (part of UV1 vaccine)
- Cancer Types Studied
- Non-small cell lung cancer, Malignant pleural mesothelioma, Ovarian cancer
- Administration Method
- Intradermal injection
- Combination Therapies
- PD-1/PD-L1 inhibitors, Nivolumab, Ipilimumab, Olaparib, Durvalumab
- Primary Endpoints
- Progression-free survival (PFS)
- Secondary Endpoints
- Overall survival (OS), Objective response rate (ORR), Disease control rate (DCR), Safety and tolerability
- Patient Population
- Adults with advanced or metastatic cancers, specific eligibility criteria vary by study
- Key Exclusion Criteria
- Prior immunotherapy, active autoimmune disorders, certain concurrent medications
What is ALREFIMOTIDE?
ALREFIMOTIDE is an investigational cancer vaccine that is being studied for the treatment of various advanced cancers. It is part of a class of drugs known as therapeutic cancer vaccines, which are designed to stimulate the body's immune system to fight cancer cells. ALREFIMOTIDE is also known by its product name UV1 and is being developed by Ultimovacs ASA.
The drug is composed of three synthetic peptides: alrefimotide, riletamotide, and tapderimotide. These peptides are designed to mimic certain proteins found on cancer cells, helping the immune system recognize and attack these cells.
How does ALREFIMOTIDE work?
ALREFIMOTIDE works by stimulating the body's immune system to recognize and attack cancer cells. The three peptides in ALREFIMOTIDE are designed to mimic specific proteins found on cancer cells. When injected into the body, these peptides trigger an immune response, teaching the immune system to recognize these proteins as foreign and dangerous.
This immune response leads to the production of T-cells, a type of white blood cell that can recognize and destroy cancer cells expressing these specific proteins. By enhancing the body's natural defense mechanisms, ALREFIMOTIDE aims to slow down or stop the growth of cancer cells and potentially shrink tumors.
What conditions is ALREFIMOTIDE being studied for?
ALREFIMOTIDE is currently being investigated for the treatment of several types of advanced cancers, including:
- Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer, accounting for about 80-85% of all lung cancers.
- Malignant pleural mesothelioma (MPM): This is a rare and aggressive cancer that affects the lining of the lungs (pleura).
- Ovarian cancer: Specifically, ALREFIMOTIDE is being studied in patients with recurrent ovarian cancer who do not have BRCA mutations.
Current Clinical Trials
ALREFIMOTIDE is currently being evaluated in several clinical trials:
- NSCLC Trial: A phase II study investigating the efficacy and safety of ALREFIMOTIDE in combination with anti-PD-1/PD-L1 treatment for patients with advanced or metastatic non-small cell lung cancer.
- Mesothelioma Trial (NIPU-study): A study evaluating ALREFIMOTIDE in combination with nivolumab and ipilimumab as second-line treatment for patients with malignant pleural mesothelioma.
- Ovarian Cancer Trial: A randomized clinical trial investigating ALREFIMOTIDE in combination with olaparib and durvalumab as maintenance therapy in patients with recurrent ovarian cancer without BRCA mutations.
How is ALREFIMOTIDE administered?
ALREFIMOTIDE is administered as an intradermal injection, which means it is injected just below the skin. The typical dose is 300 micrograms, although the total treatment period and frequency of administration may vary depending on the specific clinical trial and cancer type being treated.
Potential Side Effects
As ALREFIMOTIDE is still in clinical trials, the full range of potential side effects is not yet known. However, as with all cancer treatments, patients may experience some side effects. These could potentially include:
- Injection site reactions (redness, swelling, or pain at the injection site)
- Flu-like symptoms (fever, chills, fatigue)
- Immune-related adverse events (as ALREFIMOTIDE stimulates the immune system)
It's important to note that the safety profile of ALREFIMOTIDE is still being evaluated in clinical trials, and patients should discuss potential risks and benefits with their healthcare provider.
Conclusion
ALREFIMOTIDE represents a promising new approach in cancer treatment, leveraging the body's own immune system to fight cancer cells. While still in clinical trials, it shows potential for treating various advanced cancers, including non-small cell lung cancer, malignant pleural mesothelioma, and ovarian cancer. As research continues, ALREFIMOTIDE may offer new hope for patients with these challenging cancers.